ArticleClinical rheumatology2018
Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
Ho So et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
57 papers cite it
this paperpooled itcites it